For more information, visit follow us on Twitter and LinkedIn.Ĭautionary Note Regarding Forward-Looking Statements Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. in Cell Biology from Yale University.īlueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. in Biochemistry from University of California, Los Angeles, and a Ph.D. Ho served in corporate development roles at TCR 2 Therapeutics and Agios Pharmaceuticals and as a management consultant at LEK Consulting. Prior to joining Blueprint Medicines, Dr. During her tenure, she has played a central role in establishing and operating successful strategic partnerships with Roche, Ipsen, CStone Pharmaceuticals, and Zai Lab, as well as the acquisition of Lengo Therapeutics. Ho joined Blueprint Medicines in April 2018 as Vice President, Corporate Development, to lead business development, corporate strategy, new product planning and alliance management, and was promoted to Senior Vice President in January 2021. in Cell Biology from the Massachusetts Institute of Technology.ĭr. in Biochemistry from the University of Alberta, and a Ph.D. Lee also serves on the board of Fusion Pharmaceuticals, as a member of both the Nomination and Governance committee and Research and Development committee. Lee held product strategy and marketing roles of increasing responsibility at Algeta, Sanofi and Genzyme. Lee has served as Senior Vice President, Head of Portfolio Strategy and Program Management, responsible for providing strategic and operational leadership across the company's portfolio. During her tenure, she has been instrumental in building the company's portfolio from research-stage onwards, laying the groundwork for the commercial strategy that is driving the successful launches of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib). Lee joined Blueprint Medicines in August 2014 as Senior Director, New Product Strategy and Development and subsequently held multiple commercial roles with responsibility for strategy, operations, patient services, marketing and the precision medicine field team.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |